Transcriptional profiling of macrophages in situ in metastatic melanoma reveals localization-dependent phenotypes and function.
CD205
DEC-205
LY75
dendritic cells
macrophage
melanoma
myeloid infiltrate
spatial analysis
spatial tissue organization
transcriptomics
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
17 05 2022
17 05 2022
Historique:
received:
30
07
2021
revised:
29
11
2021
accepted:
04
04
2022
entrez:
18
5
2022
pubmed:
19
5
2022
medline:
21
5
2022
Statut:
ppublish
Résumé
Modulation of immune function at the tumor site could improve patient outcomes. Here, we analyze patient samples of metastatic melanoma, a tumor responsive to T cell-based therapies, and find that tumor-infiltrating T cells are primarily juxtaposed to CD14
Identifiants
pubmed: 35584631
pii: S2666-3791(22)00138-0
doi: 10.1016/j.xcrm.2022.100621
pmc: PMC9133468
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100621Subventions
Organisme : NCI NIH HHS
ID : R01 CA204115
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA219880
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA245211
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA034196
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA195712
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA230031
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests K.P. serves as advisory board member and a shareholder for Cue Biopharma, Inc., Cambridge, MA. J.B.: While this work was performed and the manuscript was being prepared, J.B. served on the board of directors (BOD) for Neovacs; served on the scientific advisory board (SAB) for Georgiamune LLC; served as a BOD member and a stock holder for Ascend Biopharmaceuticals; SAB member and a stock holder for Cue Biopharma; and a stock holder for Sanofi. J.B. joined Immunai in New York as their new chief scientific officer in August 2021 and is also continuing a limited affiliation with JAX until end of March 2022. R.F. is scientific advisor of EvolveImmune (an immuno oncology company), Zai labs, and GlaxoSmithKline. All additional authors declare no competing interests.
Références
Eur J Immunol. 2003 Feb;33(2):358-67
pubmed: 12548567
J Clin Invest. 2007 Sep;117(9):2517-25
pubmed: 17786242
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
Immunity. 2012 Aug 24;37(2):364-76
pubmed: 22863836
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Nat Genet. 2017 May;49(5):708-718
pubmed: 28319088
Clin Cancer Res. 2008 Dec 15;14(24):8169-77
pubmed: 19088032
Nat Rev Cancer. 2004 Jan;4(1):71-8
pubmed: 14708027
Cancer Immunol Res. 2013 Oct;1(4):201-9
pubmed: 24777851
Nature. 1998 Mar 19;392(6673):245-52
pubmed: 9521319
Nat Biotechnol. 2014 Apr;32(4):364-72
pubmed: 24633240
J Biochem. 2012 May;151(5):469-76
pubmed: 22437940
J Invest Dermatol. 2020 Jul;140(7):1327-1334
pubmed: 31881212
Annu Rev Immunol. 2013;31:563-604
pubmed: 23516985
Immunity. 2014 Jul 17;41(1):21-35
pubmed: 25035951
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Immunogenetics. 1998 May;47(6):442-50
pubmed: 9553150
Nat Rev Immunol. 2003 Jun;3(6):445-53
pubmed: 12776204
Lancet Oncol. 2016 May;17(5):651-62
pubmed: 27055731
Clin Cancer Res. 2013 Jul 1;19(13):3404-15
pubmed: 23653148
J Mol Biol. 2019 Apr 19;431(9):1792-1804
pubmed: 30660620
J Immunother Cancer. 2017 Jul 18;5(1):53
pubmed: 28716061
Cancer Discov. 2019 Aug;9(8):1102-1123
pubmed: 31197017
PLoS One. 2009 Nov 18;4(11):e7833
pubmed: 19924305
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Mol Cell Biol. 2005 Dec;25(24):10768-81
pubmed: 16314502
JCI Insight. 2016 Dec 22;1(21):e88955
pubmed: 28018970
J Exp Med. 2004 Mar 15;199(6):815-24
pubmed: 15024047
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Immunity. 2017 Dec 19;47(6):1037-1050.e6
pubmed: 29221729
Curr Opin Immunol. 2021 Feb;68:34-40
pubmed: 33035713
Cell. 2016 Mar 10;164(6):1233-1247
pubmed: 26967289
Immunity. 2007 Oct;27(4):670-84
pubmed: 17950003
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
J Clin Med. 2020 May 08;9(5):
pubmed: 32397120
Immunity. 2013 Apr 18;38(4):831-44
pubmed: 23601689
J Immunother Cancer. 2018 Nov 13;6(1):118
pubmed: 30424804
Curr Top Microbiol Immunol. 2020;429:117-145
pubmed: 31974758
Immunity. 2008 Jul 18;29(1):150-64
pubmed: 18631455
Cell Stem Cell. 2012 Dec 7;11(6):812-24
pubmed: 23168163
Cancer Res. 2018 Sep 15;78(18):5243-5258
pubmed: 30012670
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Cancer Cell. 2019 Apr 15;35(4):588-602.e10
pubmed: 30930117
J Immunol. 2009 Aug 15;183(4):2867-83
pubmed: 19635926
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Vaccine. 2019 May 1;37(19):2624-2633
pubmed: 30955979
Science. 2001 Jul 13;293(5528):253-6
pubmed: 11452116
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
J Immunol. 1998 May 1;160(9):4587-95
pubmed: 9574566
Nat Rev Drug Discov. 2021 May;20(5):384-405
pubmed: 33692549
Expert Opin Biol Ther. 2005 Oct;5(10):1303-15
pubmed: 16197336
J Exp Med. 2002 Dec 16;196(12):1627-38
pubmed: 12486105
Curr Opin Immunol. 2010 Apr;22(2):231-7
pubmed: 20144856
Nat Rev Cancer. 2016 Jul;16(7):431-46
pubmed: 27282249
Nat Methods. 2017 Sep;14(9):873-876
pubmed: 28783155
Blood. 2013 Feb 21;121(8):1422-31
pubmed: 23264595
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
Rev Diabet Stud. 2012 Winter;9(4):305-18
pubmed: 23804268